Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) announced its submission titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” was selected for a poster at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), held Dec 1–4, 2025 in San Diego.

The poster appears in Poster Session 1 (Section 11: New Therapies and Clinical Trials) with scheduled viewing from Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT. The announcement summarizes laromestrocel (Lomecel-B) as a mesenchymal stem cell product proposed to have immunomodulatory and regenerative mechanisms relevant to Alzheimer’s research.

Insights

Clinical Trials Expert

Poster selection signals early-stage clinical interest but provides limited actionable evidence.

Longeveron’s presentation at CTAD 2025 highlights a reported reduction in brain neuroinflammation after laromestrocel treatment in mild Alzheimer’s disease from the CLEAR MIND study. A poster at a scientific meeting conveys that data exist and merit discussion among researchers, but it does not by itself confirm clinical benefit or regulatory progress.

The business mechanism is straightforward: presenting mechanistic biomarker results can increase scientific visibility and support further development of a cellular therapy program. Key dependencies include the poster’s methodology, sample size, statistical robustness, and whether the biomarker changes translate to clinical outcomes; none of those details are provided here. Limitations include poster format (often preliminary), potential selection bias toward positive findings, and absence of peer‑reviewed publication or prespecified primary endpoint results.

Watch for concrete follow-ups within the next 1–12 months: availability of the full poster content at CTAD December 1-4, 2025, subsequent conference abstracts, peer‑reviewed publication of CLEAR MIND results, and any announced safety or efficacy endpoints. These items will materially clarify whether the biomarker signal supports advancement in clinical development or regulatory discussions.

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) to be held December 1-4, 2025 in San Diego, CA.

“We are excited to have been selected to present important laromestrocel data at this leading forum for Alzheimer’s research and clinical investigation,” said Joshua Hare, Co-founder, Chief Science Officer and Executive Chairman of Longeveron. “We believe the findings offer potential mechanistic and clinical insights in the development of cellular-based therapy for Alzheimer’s disease.”

Poster Presentation – Poster Session 1
Date:	Monday, December 1, 2025, 3:00 p.m. PT to Tuesday, December 2, 2025 5:30 p.m. PT
Section:	11. New Therapies and Clinical Trials
Title:	00260 “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study”

About laromestrocel (Lomecel-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that laromestrocel may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

What will Longeveron (LGVN) present at CTAD 2025 and when?

Longeveron will present a poster titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD” during Poster Session 1, available Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT.

Which CTAD 2025 session features Longeveron’s (LGVN) poster?

The poster is listed in Section 11: New Therapies and Clinical Trials as poster number 00260.

What study are the laromestrocel data from that LGVN will present at CTAD 2025?

The data come from the CLEAR MIND study, reporting reduced brain neuroinflammation after laromestrocel treatment in mild Alzheimer’s disease.

What is laromestrocel (Lomecel-B) described as in Longeveron’s CTAD 2025 announcement?

Laromestrocel is described as a living mesenchymal stem cell product derived from young adult bone marrow with proposed immunomodulatory and regenerative actions.

How can investors find Longeveron’s (LGVN) CTAD 2025 poster details on the conference dates?

The poster is scheduled during CTAD 2025, which runs Dec 1–4, 2025; session details list the poster time as Dec 1–Dec 2 in Poster Session 1.

Does Longeveron claim clinical implications for laromestrocel in Alzheimer’s in the CTAD 2025 announcement?

The company states the findings may offer mechanistic and clinical insights into cellular-based therapy development for Alzheimer’s disease.